No Data
No Data
Castle Biosciences(CSTL.US) Officer Sells US$59,278.63 in Common Stock
$Castle Biosciences(CSTL.US)$ Officer Oelschlager Kristen M sold 2,793 shares of common stock on Jul 1, 2024 at an average price of $21.224 for a total value of $59,278.63.Source: Announcement What is
Form 144 | Castle Biosciences(CSTL.US) Officer Proposes to Sell 531.34K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Castle Biosciences(CSTL.US)$ Officer Kristen Oelschager intends to sell 24,407 shares of its common stock on Jul 1, with a total market value of approximately $531.34K.
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Maintains Target Price $35
CCORF analyst Kyle Mikson CFA maintains $Castle Biosciences(CSTL.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 24.8% and a
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' TissueCypher Test
Castle's TissueCypher test has been shown to improve the risk stratification of patients with Barrett's esophagus (BE)1,2 Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FRIENDSWOOD, Texas--(BUSINESS WIRE)--$CSTL #CSTL--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on June 14,
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersNexalin Technology (NASDAQ:NXL) stock increased by 48.1% to $1.54 during Wednesday's after-market session. The company's market cap stands at $11.4 million. Tempest Therapeutics (NASDAQ:TPST) s
No Data